Loading...

Financial Statements

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO)

Healthcare

Income Statement

Download APVO income statement Download APVO income statement
Year 2013 2014 2015 2016 2017 2018
Earnings Per Share Basic ---2.93-5.550.33-2.39
Net Profit Margin -313.75-1.12-1.77-3.090.48-2.33
Earnings Per Share Diluted ---2.93-5.550.33-2.39
Revenue 0.1745.6333.6036.4314.6623.07
Weighted Average Shares Outstanding --20.2120.2421.3422.50
Gross Profit 0.1729.3816.6712.259.6511.85
Weighted Average Shares Outstanding (Diluted) --20.2320.2421.3422.50
Sales, General and Administrative Expense 15.4534.2843.0477.3369.1556.27
Dividend per Share ------
Operating Income -53.34-51.71-61.10-126.94-53.95-51.66
Gross Margin 1.000.640.500.340.660.51
Earnings before Tax -53.34-51.71-61.34-127.75-16.33-53.69
EBITDA Margin -309.83-1.09-1.74-3.39-3.47-2.14
Net Income -53.34-51.12-59.32-112.426.97-53.69
EBIT Margin -313.75-1.13-1.83-3.48-3.68-2.24
Net Income - Discounted ops ------
Profit Margin -313.75-1.12-1.76-3.090.48-2.33
Preferred Dividends ------
Free Cash Flow margin -0.00-0.00-0.00-0.00-0.00-0.00
R&D Expenses 38.0746.5934.7329.5229.0235.38
Interest Expense ----15.34-23.30-
Earnings Before Tax Margin -313.75-1.13-1.83-3.51-1.11-2.33
Consolidated Income -53.34-51.12-59.32-112.426.97-53.69
EBIT -53.34-51.71-61.34-126.94-53.95-51.66
EBITDA -52.67-49.69-58.43-123.58-50.82-49.27
Income Tax Expense --0.60-2.02-15.34-23.30-
Operating Expenses 53.5181.0977.77106.8598.1791.65
Cost of Revenue -16.2516.9324.185.0111.21
Net Income Com -53.34-51.12-59.32-112.426.97-53.69
Net Income - Non-Controlling int ------

Balance Sheet Statement

Download APVO income statement Download APVO income statement
Year 2014 2015 2016 2017 2018
Total current liabilities 19.8419.9419.5418.5117.61
Other Liabilities 8.369.86---
Long-term debt --18.3815.7319.28
Cash and cash equivalents 3.594.649.687.0930.64
Total debt --18.3819.0620.07
Cash and short-term investments 3.594.649.687.0930.74
Deferred revenue 4.547.161.62--
Inventories 17.6320.326.641.031.78
Tax Liabilities 1.8715.82---
Goodwill and Intangible Assets 25.1246.65-6.085.25
Deposit Liabilities -----
Tax assets 1.311.38---
Total non-current liabilities 5.5319.2121.7516.4619.48
Total current assets 41.5535.1371.4195.0848.69
Total liabilities 25.3639.1541.2934.9737.09
Payables 11.4710.0811.497.3511.67
Other comprehensive income --131.27155.84157.79
Short-term investments ---78.110.10
Retained earnings (deficit) -172.67-231.99-80.69-73.72-127.41
Property, Plant & Equipment Net 3.204.185.915.845.20
Total non-current assets 78.4292.6320.4421.9218.80
Other Assets 6.513.72---
Net Debt -3.59-4.648.7111.97-10.56
Investments ---78.110.10
Total shareholders equity 94.6188.6250.5782.0330.41
Total assets 119.97127.7791.86117.0167.49
Long-term investments -----
Receivables 13.826.464.282.145.22
Short-term debt ---3.330.80

Cash Flow Statement

Download APVO income statement Download APVO income statement
Year 2013 2014 2015 2016 2017 2018
Insurance (repayment) of debt ------
Net Cash/Marketcap 0.000.000.00---
Insurance (buybacks) of shares ------
Depreciation & Amortization 0.672.022.913.363.132.39
Dividend payments ------
Operating Cash Flow -51.39-47.01-48.76-36.86-41.57-51.42
Acquisitions and disposals --47.81----
Free Cash Flow -52.41-48.00-50.29-39.37-42.98-52.40
Net cash flow / Change in cash -3.591.045.04-2.5820.59
Effect of forex changes on cash ------
Financing Cash Flow 52.4199.4051.3389.309.53-0.79
Investment purchases and sales ------
Capital Expenditure -1.02-0.99-1.532.511.400.98
Stock-based compensation 0.951.071.113.814.882.14
Investing Cash Flow ------

Retained Earning Schedule

Year 2014 2015 2016 2017 2018
Retained Earnings (Previous Year) --173-232-81-74
Net Income -51-59-1127-54
Stock Dividends -122-264--
Divident Paid -----
Retained Earnings -173-232-81-74-127

PPE Schedule

Year 2014 2015 2016 2017 2018
Year 20142015201620172018
Gross PPE -3466
Annual Depreciation 43-1-1-2
Capital Expenditure -1-2311
Net PPE 34665

Intangible and Goodwill Schedule

Year 2014 2015 2016 2017 2018
Intangible and Goodwill (Previous Year) -2547-6
New Purchases -----
Intangible and Goodwill 2547-65

Aptevo Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Aptevo Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.